Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study - Summary - MDSpire
Advertisement
Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study
To examine the association between rimegepant use and changes in migraine frequency and patient-reported outcomes in a real-world clinical setting, specifically in patients with chronic and episodic migraine.
Key Findings:
All five outcome measures improved significantly from baseline to Month 3 (P = 0.001).
Monthly migraine days decreased from 17.27 to 2.90.
Monthly headache days decreased from 19.10 to 5.60.
HIT-6 scores declined from 62.27 to 45.47.
MIDAS scores decreased from 50.99 to 12.44.
MSQ scores improved from 59.94 to 86.53.
Both chronic and episodic migraine subgroups showed significant improvements across all outcomes.
Participants had a mean age of 41.12 years, with 80% being women.
Interpretation:
Every-other-day rimegepant was associated with meaningful reductions in migraine frequency and headache-related disability over 3 months in both chronic and episodic migraine patients.
Limitations:
The study is retrospective and may not reflect broader patient populations, introducing potential biases.
Limited data on long-term efficacy and safety in diverse clinical settings.
Conclusion:
Preliminary findings suggest rimegepant may be effective for migraine prevention, but further confirmation in prospective controlled studies is urgently needed.
